Effect of large graphene particle size on structure, optical property and photocatalytic activity of graphene-titanate nanotube composites

Available online 19 October 2021In this work we investigate the crystal transformation and optical properties of hydrothermal titania nanotube (TNT) when combining with large size of exfoliated graphene achieved by electrochemical process (EC-Gr). The TNT monoclinic structure has been changed to TiO2 anatase phase when TNT was grown in the presence of graphene dispersion. The effect of graphene on the evolution of TNT crystal could be understood by the interaction of carbon elements in graphene and Ti4+ ions in the titania structure. Due to the carrier separation which reduced recombination rate of excited photoelectrons and holes revealed by photoluminescence characterizations, the visible light photocatalytic activity in degradation of methylene blue in solution of the composite was enhanced. The photocatalytic enhancement was discussed and clarified based on UV–vis diffuse absorption spectra and time-resolved photoluminescence investigation.Vo Cao Minh, Phan Tan Dat, Pham Thi Thuy, Nguyen Xuan Sang, Nguyen Tri Tuan, Tran Thanh Tung, Dusan Losi

Effectiveness of GenoType MTBDRsl in excluding TB drug resistance in a clinical trial

OBJECTIVES: To assess the performance of the GenoType MTBDRsl v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial. METHODS: Direct sputum MTBDRsl results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard. RESULTS: Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDRsl and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDRsl result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) resistant and 36 (8.7%) inconclusive. There were 9 (2.3%) FQ discordant pDST/MTBDRsl results, of which 3 revealed a mutation and 5 (1.3%) SLI discordant pDST/MTBDRsl results, none of which were mutants on sequencing. Among the 17 FQ- and SLI MTBDRsl-inconclusive samples, sequencing showed 1 FQ- and zero SLI-resistant results, similar to frequencies among the conclusive MTBDRsl. The majority of inconclusive MTBDRsl results were associated with low bacillary load samples (acid-fast bacilli smear-negative or scantily positive) compared to conclusive results (P < 0.001). CONCLUSION: MTBDRsl can facilitate the rapid exclusion of FQ and SLI resistances for enrolment in clinical trials